The Cost of COPD Exacerbations Managed in Hospital

Varol, Yelda; Varol, Umut; Başer, Zeynep Munteha; Usta, Levent; Balcı, Günseli; Özacar, Rıfat

doi:10.5152/ttd.2013.04

Cited by 9 publications

(11 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The mean duration of hospitalization was 8.1 days in this study. In previous studies, the mean duration was 4.5–14.5 days 5–7,19,22–24. A longer hospital duration is also associated with increased daily costs due to treatment-resistant, severe cases with many accompanying comorbidities in addition to increased expenditures for hospital stays.…”

Section: Discussionmentioning

confidence: 93%

See 1 more Smart Citation

Clinical factors and comorbidities affecting the cost of hospital-treated COPD

Deniz

Şengül

Aydemir³

et al. 2016

COPD

View full text Add to dashboard Cite

PurposeWe aimed to assess the effects of comorbidities on COPD costs and to investigate the relationship between comorbidities and clinical variables.Patients and methodsAll patients hospitalized with a diagnosis of COPD exacerbation between January 1, 2014, and December 31, 2014, at all state hospitals of Aydın province, a city located in the western part of Turkey, were included in this study. The costs examined in the study pertained to medications, laboratory tests, hospital stays, and other treatment-related factors, such as consumption of materials, doctor visits, and consultation fees.ResultsA total of 3,095 patients with 5,237 exacerbations (mean age, 71.9±10.5 years; 2,434 males and 661 females) were evaluated. For 880 of the patients (28.9%), or 3,852 of the exacerbations (73.1%), at least one comorbid disease was recorded. The mean cost of each exacerbation was $808.5±1,586, including $325.1±879.9 (40.7%) for hospital stays, $223.1±1,300.9 (27.6%) for medications, $46.3±49.6 (0.9%) for laboratory expenditures, and $214±1,068 (26.5%) for other treatment-related factors, such as consumption of materials, doctor visits, and consultation fees. The cost of each exacerbation was $1,014.9 in patients with at least one comorbidity, whereas it was $233.6 in patients without comorbidity (P<0.001). Age >65 years, female gender, hospitalization in an intensive care unit, invasive or noninvasive mechanical ventilation, and a long duration of hospitalization were all found to be significant factors in increasing total costs during the exacerbations requiring hospitalization (P<0.05 for all).ConclusionComorbidities have an important role in the total costs of acute exacerbations of COPD. Strategies for the prevention, diagnosis, and effective management of comorbidities would decrease the overall financial burden associated with acute exacerbations of COPD.

show abstract

Section: Discussionmentioning

confidence: 93%

“…In this study, the total cost of hospitalization due to COPD exacerbations was found to be $808. Previous studies have reported a wide range of cost per hospitalization (between $612 and $9,545) 5–7,19–24…”

Section: Discussionmentioning

confidence: 99%

Clinical factors and comorbidities affecting the cost of hospital-treated COPD

Deniz

Şengül

Aydemir³

et al. 2016

COPD

View full text Add to dashboard Cite

show abstract

“…An association between age of patients with COPD and increase in healthcare resource utilisation was observed, whereas gender was not considered as an independent predictor of healthcare resource utilisation [42][43][44][45]. Readmission at least twice in the first year of follow-up was observed among 9 % of total patients with COPD studied and was related to increasing age and male gender [46].…”

Section: Impact Of Demographic Characteristicsmentioning

confidence: 93%

Systematic Review of Humanistic and Economic Burden of Symptomatic Chronic Obstructive Pulmonary Disease

Srivastava¹,

Thakur²,

Sharma³

et al. 2015

PharmacoEconomics

View full text Add to dashboard Cite

show abstract

“…Considering the studies performed in Turkey, the mean total cost was found to be 1,833.85 TL in a study conducted by Varol et al (15), in which 376 patients with COPD exacerbation who were hospitalized in the Clinic of Thoracic Diseases during 12 months between 2005 and 2006 were evaluated. Also, in their study, the total cost per patient was found to be higher in the group using antibiotics than in the group not using antibiotics.…”

Section: Discussionmentioning

confidence: 99%

Costs of the Patients Hospitalized with Acute Exacerbations of Chronic Obstructive Pulmonary Disease in a University Hospital

Yıldırım¹,

Türk²,

Öztürk³

2015

Eurasian J Pulmonol

View full text Add to dashboard Cite

Objective: Chronic obstructive pulmonary disease (COPD), although a preventable and treatable disease continues to be a major health problem. Acute exacerbations of COPD is a major cause of hospitalization of patients and it constitutes a significant portion of COPD-related health care costs. In this study, we aimed to determine the cost of patients hospitalized with acute exacerbations of COPD in a university hospital. Methods:Data of the patients that were hospitalized due to COPD exacerbation between 1 September 2013-1 September 2014 in Hospital of Gazi University Medical Faculty were retrospectively analyzed. Cost data were gathered from data processing department. Costs were identified for drugs, laboratory tests, bed costs and other materials.Results: A total of 790 patients were hospitalized during twelve months. Among these patients 181 (23.0%) patients had COPD and 99 (12.5%) were hospitalized due to acute exacerbation of COPD. Of these 99 patients 77 (77.8%) were male and 22 (22.2%) were female. Forty-nine (49.5%) patients were hospitalized from the emergency department, 50 (50.5%) patients were from the outpatient clinic. The median age was 70 (64-77) years old and median length of hospital stay was 8 (6-13) days. Ninety-one (91.9%) of them were discharged from the service. Eight (8.1%) patients were transfered to the intensive care unit (ICU) due to respiratory failure, and 7 of these patients (7.4%) hospitalized back to the service after treatment at ICU, 2 (2.1%) patients died. The median cost per patient was 1.064 (726-1.866) Turkish Lira (TL). Drug costs accounted the largest portion (36.0%) of the median cost, followed by bed cost (26.0%). Two (2.1%) of patients died in hospital. Although the number of patients without antibiotic usage is less (17.2% vs 82.8%); the median cost per patient in the antibiotic using group was higher than that were without antibiotic using (median 643 vs 1.162 TL p=0.001). Presence of a comorbidity, hypoxemia, noninvasive mechanical ventilation (NIMV) requirement were existing factors that didn't increase the cost of patients (p>0.05). Only the use of antibiotics was detected as independent factors that increase the total cost (95% CI 0.487 to 12.984, p=0.030). Conclusion:Acute exacerbation of COPD continues to be an important cause of mortality and economic burden in the hospitalized COPD patients in pulmonary clinics.

show abstract

The Cost of COPD Exacerbations Managed in Hospital

Cited by 9 publications

References 15 publications

Clinical factors and comorbidities affecting the cost of hospital-treated COPD

Clinical factors and comorbidities affecting the cost of hospital-treated COPD

Systematic Review of Humanistic and Economic Burden of Symptomatic Chronic Obstructive Pulmonary Disease

Costs of the Patients Hospitalized with Acute Exacerbations of Chronic Obstructive Pulmonary Disease in a University Hospital

Contact Info

Product

Resources

About